We interrupt all the bad news about COVID with this from the Institute for Health Metrics and Evaluation: surviving the virus has improved dramatically since the early days of the pandemic.

The likelihood of someone dying from COVID-19 has declined by a third.

In an interview with Reuters news agency, IHME Director Dr. Christopher Murray said 0.6% of those infected with the virus die, compared to 0.9% last spring. Improvements in treatment, including the use of blood thinners, oxygen and the generic steroid dexamethasone are a large part of the reason for the decline, he said.

Two research studies of patients in New York and in the UK bear out the positive news, finding sharp decreases in mortality.

Published last month in the Journal of Hospital Medicine, the New York City study found an 18% decline in COVID deaths since March among 5,121 hospitalizations.

second study released just recently found a 20% decrease in mortality among hospitalized patients in England in June compared to the beginning of the pandemic in April.

US Covid Deaths Decline - blog.jpg

“I would classify this as a silver lining to what has been quite a hard time for many people,” Bilal Mateen, a data science fellow at the Alan Turing Institute in the United Kingdom, told NPR.

Leora Horwitz, M.D., an author of the New York City study, echoed those findings. “We find that the death rate has gone down substantially,” she told NPR. “I do think this is good news,” she said, adding, “but it does not make the coronavirus a benign illness.”

The Institute of Health Metrics and Evaluation, based at the University of Washington, cautions that with the advancing winter months, it expects the infection rate globally to increase to 4 million new cases a day. It estimates daily deaths will reach over 15,000 a day in mid-January declining to under 13,000 by March 1.

“If universal mask coverage (95%) were attained [by last week], our model projects 571,000 lives could be saved by March 1, 2021,” the Institute said in its weekly global report.

Specifically in the United States, another Institute report predicts “daily deaths to reach 2,200 in mid-January and slowly decline to 1,750 on March 1… we expect daily infections to reach 325,000 by early January.”

Estimating national mask use at 67% — lower than many other organizations have found – the IHME report projects the US could save 68,000 lives by March 1 if 95% of the population wore masks.

CDC report released at the end of October said that as of June, 88.7% of the US population wore masks. Even among the youngest group surveyed, those 18-29, 86.1% wore masks.

Photo by Online Marketing on Unsplash


author avatar
Green Key
Jun 6, 2023

Statins Show Promise in Reducing Death from Ovarian Cancer

Women with ovarian cancer who take statins to lower their cholesterol have a 40% lower death rate.

“These drugs are appealing as they are widely used, inexpensive, and well tolerated in most patients. The associated reduction in ovarian cancer mortality is promising,” said Dr. Kala Visvanathan, lead researcher of a new study presented last week during the American Association for Cancer Research Virtual Annual Meeting II.

Dr. Visvanathan, professor of epidemiology and oncology at Johns Hopkins Bloomberg School of Public Health and Sidney Kimmel Comprehensive Cancer Center in Baltimore, said all statins reduced the risk of dying, with lipophilic statins such as simvastatin and lovastatin, decreasing the likelihood by an average 43%. The most significant reductions occurred in those with high-grade serous carcinoma (40% reduction in mortality) and endometrioid ovarian cancer (50% reduction.)

The findings are the most comprehensive to date and add support to other, smaller studies showing similar improvements in ovarian cancer mortality from statins.

Most recently, a team of researchers at Australia’s QIMR Berghofer Medical Research Institute, analyzed 36 studies of several common medications taken by ovarian cancer patient. They concluded statin use showed the most promise. “Statin use is associated with better ovarian cancer survival,” they wrote in an article this month in Gynecologic Oncology, cautioning that, “Further study, preferably a clinical trial, is required.”

At the AACR meeting, Visvanathan said her team reviewed data on 10,062 ovarian cancer patients from the Finnish national cancer registry. 2,621 used statins, and 80% of those used lipophilic statins.

“Our results provide further evidence in support of the clinical evaluation of lipophilic statins as part of the treatment of ovarian cancer,” Visvanathan said.

Ovarian cancer is a rare cancer type, accounting for only about 1.2% of cancer cases diagnosed in the United States each year. Its five year survival rate is less than 50% because of the difficulty of diagnosing it until it has progressed to an advanced stage.


author avatar
Green Key